WHU graduate founds biotech start-up: 8 million euros for cancer research!

WHU graduate founds biotech start-up: 8 million euros for cancer research!

The founding of Akribion ​​Therapeutics in 2024 represents a significant step in the field of biopharmaceutical innovation. The company, founded by WHU alumnus Lukas Linnig (EMBA 2022) and an experienced founding team, aims to develop new processes to combat cancer cells while sparing healthy cells. The basis of these developments is based on the special enzyme G-dase E, which specifically attacks diseased cells and is therefore intended to offer precise therapy. WHU reports that the company emerged from BRAIN Biotech AG in Hesse in order to improve strategic direction and drug development.

A current round of seed financing brought the start-up eight million euros, which will be used to further develop the technology. The lead investors include CARMA FUND and RV Invest, as well as other investors such as the High-Tech Gründerfonds. Starting hub Hesse highlights that this financing round not only supports the development of an RNA-controlled technology for targeted cell destruction, but also demonstrates the company's market potential and scientific basis.

Technology and goals

Akribion ​​Therapeutics is pursuing the development of an RNA-directed, nuclease-based technology that enables programmable cell depletion. This technology will be used in particular in cancer research. Lukas Linnig, co-founder and co-CEO, emphasizes the specialist depletion of certain cell subgroups, which is based on RNA sequences. The first clinical trials are planned within the next five years, with the aim of approval within a decade, underscoring the company's gradual progress. The shareholder mentions that the company wants to provide proof of concept in vivo with their technology.

The need to spin off Akribion ​​results from the differentiation between strategies for drug development and industrial biotechnology projects. Akribion ​​needs independence to enable targeted investments in new therapeutics. WHU's EMBA program has given founders valuable tools to strategically manage their company and operate successfully in the biotechnological sector.

Market potential and future prospects

The successful fundraising round creates promising prospects for Akribion ​​Therapeutics. The positive market reception and the great interest of investors underline the trust in the company's scientific foundations. With the new funds, Akribion ​​is well positioned to pursue its ambitious goals in a dynamic market.

In conclusion, Akribion ​​Therapeutics is not only developing a promising technology, but is also strategically and financially well positioned to make a significant contribution to the field of cancer research. The next phase of its development is approaching, and those involved have high hopes for the innovative power of the company.